Paper · 28317403
Intrahepatic cholangiocarcinoma: current management and emerging therapies.
Rahnemai-Azar AA and 4 others. Expert Rev Gastroenterol Hepatol, 2017. Cited by 50 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Intrahepatic cholangiocarcinoma: current management and emerging therapies. Papers, record 28317403. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28317403
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Bile Duct Neoplasms | Major topic |
| Cholangiocarcinoma | Major topic |
| Hepatectomy | Major topic |
| Liver Transplantation | Major topic |
| Molecular Targeted Therapy | Major topic |
| Biomarkers, Tumor | |
| Genetic Predisposition to Disease | |
| Humans | |
| Molecular Diagnostic Techniques | |
| Phenotype | |
| Precision Medicine | |
| Predictive Value of Tests | |
| Signal Transduction |
Source PubMed
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References0
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
None in this release.
Cited by32
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 50 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41,767,584 | Comprehensive identification of microbial and metabolomic factors impacting ICC recurrence. | Front Oncol | 2025 | https://conductscience.org/library/papers/41767584 | PubMed |
| 41,226,789 | Expanding Horizons in Cholangiocarcinoma: Emerging Targets Beyond FGFR2 and IDH1. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/41226789 | PubMed |
| 41,164,952 | FXYD3 Promotes Tumor Progression by Binding With IRF7 to Regulate JAK2/STAT5 Signaling in Intrahepatic Cholangiocarcinoma. | Adv Sci (Weinh) | 2026 | https://conductscience.org/library/papers/41164952 | PubMed |
| 39,184,062 | Endoscopic ultrasound with tissue acquisition of lymph nodes in patients with potentially resectable intrahepatic cholangiocarcinoma. | Endosc Int Open | 2024 | https://conductscience.org/library/papers/39184062 | PubMed |
| 37,679,641 | Radiomics nomogram based on optimal VOI of multi-sequence MRI for predicting microvascular invasion in intrahepatic cholangiocarcinoma. | Radiol Med | 2023 | https://conductscience.org/library/papers/37679641 | PubMed |
| 37,156,579 | Influence of surgical margin width on survival rate after resection of intrahepatic cholangiocarcinoma: a systematic review and meta-analysis. | BMJ Open | 2023 | https://conductscience.org/library/papers/37156579 | PubMed |
| 37,034,966 | Endoscopic biliary treatment of unresectable cholangiocarcinoma: A meta-analysis of survival outcomes and systematic review. | World J Gastrointest Endosc | 2023 | https://conductscience.org/library/papers/37034966 | PubMed |
| 36,773,271 | Development and validation of combined Ki67 status prediction model for intrahepatic cholangiocarcinoma based on clinicoradiological features and MRI radiomics. | Radiol Med | 2023 | https://conductscience.org/library/papers/36773271 | PubMed |
| 35,883,086 | Aggregation-induced emission photosensitizer-based photodynamic therapy in cancer: from chemical to clinical. | J Nanobiotechnology | 2022 | https://conductscience.org/library/papers/35883086 | PubMed |
| 35,280,821 | A Multi-Parametric Radiomics Nomogram for Preoperative Prediction of Microvascular Invasion Status in Intrahepatic Cholangiocarcinoma. | Front Oncol | 2022 | https://conductscience.org/library/papers/35280821 | PubMed |
1 to 10 of 32
See all 32 cited byGenes0
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
None in this release.
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/28317403
GET https://conductscience.org/api/papers/v1/28317403/cited_by?page=2